MoonLake Immunotherapeutics Class A financial statements

문레이크 이뮤노테라퓨틱스NASDAQ:MLTX · Nasdaq · Healthcare · sector #16
$10.95-3.78%
2026-10-06 close · prelim

MoonLake Immunotherapeutics Class A's published financial data is dated 2026-10-04. 2024 revenue was $0M. 2024 operating profit was −$143M.

Reported results

MoonLake Immunotherapeutics Class A notifications

Quantus Signal · live data · not investment advice · Privacy Policy
Q